Moderna Stock Rises 6.6% as FDA Begins Review of Flu Vaccine

Moderna's stock experienced a 6.6% increase following the announcement that the U.S. Food and Drug Administration (FDA) has initiated a review of the company's flu vaccine. According to Jin10, this development marks a significant step for Moderna as it seeks to expand its vaccine portfolio beyond COVID-19. The FDA's review process is crucial for Moderna's efforts to bring its flu vaccine to market, potentially enhancing its position in the pharmaceutical industry. Investors are closely monitoring the situation, anticipating the potential impact on Moderna's future growth and market share.